Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-01-26 @ 1:54 PM
Study NCT ID:
NCT02718820
Status:
COMPLETED
Last Update Posted:
2024-01-09
First Post:
2016-03-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Sponsor:
Medical University of Vienna
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
PemDoc II
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None